AstraZeneca’s drug Fasenra (benralizumab) has been approved in the European Union as an additional treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA).
Takeda announced positive interim results from a Phase 3-enabling proof-of-concept study for mezagitamab (TAK-079), an anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN).
The FDA has expanded approval for Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to include adults aged 18–59 years who are at higher risk of lower respiratory tract disease from the virus due to chronic conditions.
BirchBioMed announced the authorisation from Health Canada to conduct its Phase II/III randomised clinical trial of a naturally based compound, FS2, at multiple centres of expertise throughout Canada.
Bioptimus announced that its H-optimus-0 foundation model is now integrated into Proscia’s Concentriq Embeddings, enabling data scientists and researchers in pathology and life sciences to achieve breakthroughs in AI development.
Yourgene Health announced that it has received accreditation under the new EU requirements of the in vitro diagnostic regulation (IVDR) for the Yourgene Cystic Fibrosis Base assay.
The results showed that Ellorarxine significantly increases MAP2 expression at remarkably low concentrations (10nM), induces neurite outgrowth, increases mitochondrial viability to combat oxidative stress, ameliorates neuroinflammation and modifies G
SGS, a testing, inspection and certification company, announced it will be an exhibitor at the Convention on Pharmaceutical Ingredients (CPHI) Milan 2024.
